Table 2.
Characteristics matching in Risperidone ISM versus Paliperidone palmitate comparison, for the tolerability base case analysis
| Study | PRISMA-3 OLE (Full population) | Gopal 2010 [28] | |
|---|---|---|---|
| Intervention | Risperidone ISM | PP | |
| Characteristic | Pre-matching (N = 215) | Post-matching (ESS = 42) | (N = 388) |
| Age [Mean (SD)] | 39.1 (10.9) | 37.3 (10.8) | 37.3 (10.8) |
| Baseline PANSS total score [Mean (SD)] | 71.3 (14.8) | 58.2 (18.2) | 58.2 (18.2) |
| Baseline CGI-S score [Median] | 3.0 | 3.0 | 3.0 |
| Race: white [%] | 84.7 | 69.0 | 69.0 |
CGI-S clinical global impressions—severity scale, ESS effective sample size, MAIC matching-adjusted indirect comparison, OLE open-label extension, PANSS positive and negative syndrome scale, PP paliperidone palmitate, SD standard deviation